Skip to content

Our Science

MAKING AN IMPACT WITH NEXT-GENERATION TUMOR-ACTIVATED THERAPEUTICS

We are proud to be ushering in a new era of tumor-targeting, systemically administered, conditionally activated therapeutics with the potential to deliver more effective and less toxic treatments for patients with cancer.

We start with the unmet need first – patients whose cancer is not responding to currently available treatments - and applying our scientific insights on cancer immunology to determine how to expand the repertoire of effective therapies.

Our proprietary PREDATOR™ protein engineering technology integrates specialized protein design elements to enhance activity, stability and tumor selectivity within a single molecule.
With the PREDATOR™ platform we are now able to:
1
Design potent immune modulators that remain inactive in the systemic circulation
2
Achieve excellent exposure in tumors through optimized pharmaceutical properties
3
Selectively deliver fully-potent immune stimulators upon activation by the tumor micro-environment
We are developing well-validated pro-inflammatory cytokine and costimulatory receptor agonists in a conditionally-activated format to stimulate potent anti-tumor responses without eliciting normal tissue damage, to achieve maximum therapeutic potential.